MannKind 향후 성장

Future 기준 점검 4/6

MannKind은 연간 수입과 매출이 각각 28.6%와 12.9% 증가할 것으로 예상되고 EPS는 연간 27%만큼 증가할 것으로 예상됩니다.

핵심 정보

28.6%

이익 성장률

27.05%

EPS 성장률

Biotechs 이익 성장	25.3%
매출 성장률	12.9%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	18 Sep 2025

최근 향후 성장 업데이트

Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

May 11

MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next

Mar 01

Recent updates

MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump

Sep 03

MannKind Corporation: A Post-Q2 Assessment

Aug 06

Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

May 11

MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next

Mar 01

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 17

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18

Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability

Sep 12 Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14

이익 및 매출 성장 예측

NasdaqGM:MNKD - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	405	59	113	120	6
12/31/2026	379	47	71	92	6
12/31/2025	326	33	63	82	7
6/30/2025	302	33	29	35	N/A
3/31/2025	298	30	22	29	N/A
12/31/2024	286	28	33	43	N/A
9/30/2024	267	22	29	42	N/A
6/30/2024	248	12	18	41	N/A
3/31/2024	225	8	3	40	N/A
12/31/2023	199	-12	-8	34	N/A
9/30/2023	177	-31	-32	10	N/A
6/30/2023	158	-47	-57	-27	N/A
3/31/2023	128	-71	-72	-61	N/A
12/31/2022	100	-87	-88	-81	N/A
9/30/2022	76	-98	-98	-91	N/A
6/30/2022	66	-88	-89	-78	N/A
3/31/2022	70	-94	-83	-67	N/A
12/31/2021	75	-81	-73	-62	N/A
9/30/2021	81	-79	-60	-49	N/A
6/30/2021	75	-86	-54	-47	N/A
3/31/2021	66	-61	-35	-30	N/A
12/31/2020	65	-57	-33	-28	N/A
9/30/2020	63	-45	-34	-33	N/A
6/30/2020	62	-44	-73	-72	N/A
3/31/2020	62	-46	-91	-88	N/A
12/31/2019	63	-52	-91	-88	N/A
9/30/2019	63	-47	-61	-58	N/A
6/30/2019	53	-61	-22	-20	N/A
3/31/2019	42	-71	N/A	-28	N/A
12/31/2018	28	-87	N/A	-38	N/A
9/30/2018	16	-110	N/A	-93	N/A
6/30/2018	13	-119	N/A	-102	N/A
3/31/2018	12	-131	N/A	-95	N/A
12/31/2017	11	-117	N/A	-65	N/A
9/30/2017	20	-31	N/A	-48	N/A
6/30/2017	180	129	N/A	-47	N/A
3/31/2017	178	134	N/A	-39	N/A
12/31/2016	175	126	N/A	-78	N/A
9/30/2016	162	-205	N/A	-88	N/A
6/30/2016	N/A	-364	N/A	-85	N/A
3/31/2016	N/A	-363	N/A	-91	N/A
12/31/2015	N/A	-368	N/A	-57	N/A
9/30/2015	N/A	-128	N/A	-70	N/A
6/30/2015	N/A	-133	N/A	50	N/A
3/31/2015	N/A	-177	N/A	44	N/A

애널리스트 향후 성장 전망

수입 대 저축률: MNKD 의 연간 예상 수익 증가율(28.6%)이 saving rate(3.1%)보다 높습니다.

수익 vs 시장: MNKD 의 연간 수익(28.6%)이 US 시장(15.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: MNKD 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: MNKD 의 수익(연간 12.9%)이 US 시장(연간 9.8%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: MNKD 의 수익(연간 12.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: MNKD의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/05 09:18
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

MannKind Corporation는 29명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Thomas Russo	Baird
Stephen V. Byrne	BofA Global Research
null null	BTIG

MannKind 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next

Price target increased by 9.8% to US$7.25

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Consensus forecasts updated

Recent updates

MannKind Corporation Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, Effective September 29, 2025

MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump

MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million.

MannKind Corporation announced that it expects to receive $200 million in funding

MannKind Corporation: A Post-Q2 Assessment

MannKind Corporation to Report Q2, 2025 Results on Aug 06, 2025

MannKind Corporation(NasdaqGM:MNKD) dropped from Russell 3000E Index

Mannkind Corporation to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) At American Diabetes Association's 85Th Scientific Sessions in Chicago, June 20-23

Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

MannKind Corporation to Report Q1, 2025 Results on May 08, 2025

MannKind Corporation, Annual General Meeting, May 14, 2025

MannKind Corporation Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza at the ATTD Conference, March 19-22

MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next

MannKind Corporation has filed a Follow-on Equity Offering in the amount of $200 million.

MannKind Corporation to Report Q4, 2024 Results on Feb 26, 2025

Mannkind Corporation Announces Resignation of Lauren Sabella as Executive Vice President, Operations, Effective July 18, 2025

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

MannKind Corporation to Report Q3, 2024 Results on Nov 07, 2024

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Mannkind Corporation Announces Top-Level 30-Week Results from Its Phase 4 Inhale-3 Study

MannKind Corporation Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability

Mannkind Corporation Announces Board Changes, September 30, 2024

MannKind Corporation to Report Q2, 2024 Results on Aug 07, 2024

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study

MannKind Outperforms As Tyvaso DPI Captures Market Share

New major risk - Financial position

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation to Report Q1, 2024 Results on May 08, 2024

MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

MannKind Corporation, Annual General Meeting, May 15, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024

MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

CEO & Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes

MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023

Price target increased by 9.8% to US$7.25

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023

Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)

CEO & Director notifies of intention to sell stock

Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Full year 2022 earnings: EPS misses analyst expectations

MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Mannkind Corporation: Ready For Your Biotech Portfolio

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed